TABLE OF CONTENTS
| | | | Volume 118, Issue 8 | | In this issue Editorial Article Correspondence Also new AOP | | | | | Editorial | | | Population attributable fractions continue to unmask the power of prevention Freddie Bray & Isabelle Soerjomataram British Journal of Cancer 2018 118 :1031 - 1032; March 23, 2018; 10.1038/s41416-018-0062-5 Abstract | Full Text | | | | | Germline mutations as potential causes of childhood solid tumours: comments on the Norwegian childhood cancer cohort study Yaddanapudi Ravindranath & Logan G Spector British Journal of Cancer 2018 118 :1033 - 1034; March 29, 2018; 10.1038/s41416-018-0059-0 Abstract | Full Text | | Article | | | A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin et al. British Journal of Cancer 2018 118 :1035 - 1041; March 13, 2018; 10.1038/s41416-018-0006-0 Abstract | Full Text | | | | | Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial Michael L. Maitland, Sarina Piha-Paul, Gerald Falchook, Razelle Kurzrock, Ly Nguyen et al. British Journal of Cancer 2018 118 :1042 - 1050; March 19, 2018; 10.1038/s41416-018-0020-2 Abstract | Full Text | | | | | Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma Brigette Ma, Edwin P Hui, Ann King, Sing F Leung, Michael KM Kam et al. British Journal of Cancer 2018 118 :1051 - 1055; March 20, 2018; 10.1038/s41416-018-0026-9 Abstract | Full Text | | | | | Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer Andrés J. Muñoz Martín, Israel Ortega, Carme Font, Vanesa Pachón, Victoria Castellón et al. British Journal of Cancer 2018 118 :1056 - 1061; March 28, 2018; 10.1038/s41416-018-0027-8 Abstract | Full Text | | | | | DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells Angelique Bruyer, Ken Maes, Laurie Herviou, Alboukadel Kassambara, Anja Seckinger et al. British Journal of Cancer 2018 118 :1062 - 1073; March 02, 2018; 10.1038/s41416-018-0025-x Abstract | Full Text | | | | | Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation Elisabeth F. P. Peterse, Bertine Niessen, Ruben D. Addie, Yvonne de Jong, Arjen H. G. Cleven et al. British Journal of Cancer 2018 118 :1074 - 1083; March 26, 2018; 10.1038/s41416-018-0050-9 Abstract | Full Text | | | | | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy N. O. Elander, K. Aughton, P. Ghaneh, J. P. Neoptolemos, D. H. Palmer et al. British Journal of Cancer 2018 118 :1084 - 1088; March 09, 2018; 10.1038/s41416-018-0005-1 Abstract | Full Text | | | | | A shift from papillary to reticular fibroblasts enables tumour–stroma interaction and invasion Marieke Hogervorst, Marion Rietveld, Frank de Gruijl & Abdoelwaheb El Ghalbzouri British Journal of Cancer 2018 118 :1089 - 1097; March 19, 2018; 10.1038/s41416-018-0024-y Abstract | Full Text | | | | | Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry Isabel Quiros-Gonzalez, Michal R Tomaszewski, Sarah J. Aitken, Laura Ansel-Bollepalli, Leigh-Ann McDuffus et al. British Journal of Cancer 2018 118 :1098 - 1106; March 26, 2018; 10.1038/s41416-018-0033-x Abstract | Full Text | | | | | An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes Balázs Győrffy, Lőrinc Pongor, Giulia Bottai, Xiaotong Li, Jan Budczies et al. British Journal of Cancer 2018 118 :1107 - 1114; March 21, 2018; 10.1038/s41416-018-0030-0 Abstract | Full Text | | | | | The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes Rokaya El Ansari, Madeleine L. Craze, Maria Diez-Rodriguez, Christopher C. Nolan, Ian O. Ellis et al. British Journal of Cancer 2018 118 :1115 - 1122; March 16, 2018; 10.1038/s41416-018-0038-5 Abstract | Full Text | | | | | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study Suzanne C. Dixon-Suen, Christina M. Nagle, Aaron P. Thrift, Paul D. P. Pharoah, Ailith Ewing et al. British Journal of Cancer 2018 118 :1123 - 1129; March 20, 2018; 10.1038/s41416-018-0011-3 Abstract | Full Text | | | | | The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015 Katrina F. Brown, Harriet Rumgay, Casey Dunlop, Margaret Ryan, Frances Quartly et al. British Journal of Cancer 2018 118 :1130 - 1141; March 23, 2018; 10.1038/s41416-018-0029-6 Abstract | Full Text | | | | | Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes Chitra Joseph, Olivia Macnamara, Madeleine Craze, Roslin Russell, Elena Provenzano et al. British Journal of Cancer 2018 118 :1142 - 1151; March 28, 2018; 10.1038/s41416-018-0041-x Abstract | Full Text | | Correspondence | | | Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses' Willi Sauerbrei & Tim Haeussler British Journal of Cancer 2018 118 :1152 - 1153; March 15, 2018; 10.1038/s41416-018-0023-z Abstract | Full Text | | | | | Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’’ E. S. Papadakis, T. Reeves, N. H. Robson, T. Maishman, G. Packham et al. British Journal of Cancer 2018 118 :1154 - 1154; March 15, 2018; 10.1038/s41416-018-0032-y Abstract | Full Text | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | |
No comments:
Post a Comment